GoAI
Get started
Abeona Therapeutics Inc. logo

Abeona Therapeutics Inc.

ABEO

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$6.09

+$0.13 · +2.18%

Aug 21, 4:00 PM ET

ABEO company overview

Historical prices · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

51

Fair Value

Momentum

75

Gaining

Sentiment

41

Mixed

Risk resilience

55

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Vishwas Seshadri
Listed since
Sep 19, 1980
Employees
226

Market position

Day range

Current $6.09

52-week range

Current $6.09

Open
$6.03
Previous close
$5.96
Volume
894.8K
0.7× average
Average volume
1.29M
Average daily volume
Market cap
347.1M USD
Beta
1.34
Market reference 1
50-day average
$6.354
-4.15% below average
200-day average
$5.4163
+12.44% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
225.59M USD
P/E (TTM)
-5.36×
P/B (TTM)
2.71×
P/S (TTM)
13.6×
EV / EBITDA
2.87×
Earnings yield
25.51%
Free cash flow yield
-30.21%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
56.63%
Operating margin
-327.64%
Net margin
-246.42%
Return on equity
44.71%
Return on assets
32.42%
Return on invested capital
-43.98%

Financial health

Debt / equity
0.16×
Current ratio
6.93×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends1705%-224%-2154%-4083%Gross margin, FY2021: 100.00%Gross margin, FY2022: 68.18%Gross margin, FY2023: 54.14%Gross margin, FY2025: 73.68%Operating margin, FY2021: -2994.53%Operating margin, FY2022: -3600.78%Operating margin, FY2023: -1346.71%Operating margin, FY2025: -1536.91%Net margin, FY2021: -2831.20%Net margin, FY2022: -2807.36%Net margin, FY2023: -1548.23%Net margin, FY2025: 1223.08%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 100.00%. Gross margin FY2022 68.18%. Gross margin FY2023 54.14%. Gross margin FY2025 73.68%. Operating margin FY2021 -2994.53%. Operating margin FY2022 -3600.78%. Operating margin FY2023 -1346.71%. Operating margin FY2025 -1536.91%. Net margin FY2021 -2831.20%. Net margin FY2022 -2807.36%. Net margin FY2023 -1548.23%. Net margin FY2025 1223.08%.

Income trends

Revenue

5.82M USD+66.29%

Operating income

−89.45M USD-39.30%

Net income

71.18M USD+134.92M USD
Income trends across reported periods87.28M USD22.88M USD−41.53M USD−105.94M USDRevenue, FY2021: 3M USDRevenue, FY2022: 1.41M USDRevenue, FY2023: 3.5M USDRevenue, FY2025: 5.82M USDOperating income, FY2021: −89.84M USDOperating income, FY2022: −50.92M USDOperating income, FY2023: −47.14M USDOperating income, FY2024: −64.21M USDOperating income, FY2025: −89.45M USDNet income, FY2021: −84.94M USDNet income, FY2022: −39.7M USDNet income, FY2023: −54.19M USDNet income, FY2024: −63.73M USDNet income, FY2025: 71.18M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 3M USD. Revenue FY2022 1.41M USD. Revenue FY2023 3.5M USD. Revenue FY2025 5.82M USD. Operating income FY2021 −89.84M USD. Operating income FY2022 −50.92M USD. Operating income FY2023 −47.14M USD. Operating income FY2024 −64.21M USD. Operating income FY2025 −89.45M USD. Net income FY2021 −84.94M USD. Net income FY2022 −39.7M USD. Net income FY2023 −54.19M USD. Net income FY2024 −63.73M USD. Net income FY2025 71.18M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue5.82M USD—3.5M USD1.41M USD3M USD
Cost of goods sold1.53M USD2.91M USD1.61M USD450K USD—
Gross profit4.29M USD−2.91M USD1.9M USD964K USD3M USD
Research and development26.81M USD34.36M USD31.09M USD28.97M USD38.73M USD
Selling, general, and administrative65.03M USD29.85M USD19M USD17.26M USD21.64M USD
Operating expenses93.74M USD61.3M USD49.03M USD51.88M USD92.84M USD
Interest income5.56M USD4.25M USD2.12M USD431K USD40K USD
Interest expense3.74M USD4.21M USD418K USD736K USD3.66M USD
Depreciation and amortization3.56M USD2.91M USD3.2M USD4.58M USD4.46M USD
Operating income−89.45M USD−64.21M USD−47.14M USD−50.92M USD−89.84M USD
Net income71.18M USD−63.73M USD−54.19M USD−39.7M USD−84.94M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
64%
7 beats, 4 misses, 0 met estimates
Average EPS surprise
+35.92%
11 comparable reports
Latest EPS result
-0.35
Estimate -0.23 · Miss by 51.08%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates1.881.070.25-0.56Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 20, 2025: actual -0.24, estimate -0.348, surprise +31.03%, Beat. Q2 2025, reported May 14, 2025: actual -0.24, estimate -0.35, surprise +31.43%, Beat. Q3 2025, reported Aug 11, 2025: actual 1.71, estimate -0.39, surprise +538.46%, Beat. Q4 2025, reported Nov 12, 2025: actual -0.1, estimate -0.27, surprise +62.96%, Beat. Q1 2026, reported Mar 17, 2026: actual -0.34, estimate -0.35, surprise +2.86%, Beat. Q2 2026, reported May 13, 2026: actual -0.3, estimate -0.33, surprise +9.09%, Beat. Q3 2026, reported Aug 13, 2026: actual -0.35, estimate -0.232, surprise -51.08%, Miss. Q4 2026, reported Nov 11, 2026: actual —, estimate -0.17, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates17.13M11.45M5.77M85KQ4 '24EstimateQ1 '25EstimateQ3 '25MissQ4 '25EstimateQ1 '26BeatQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q4 2024, reported Nov 14, 2024: actual —, estimate 100K USD, surprise —, Comparison unavailable. Q1 2025, reported Mar 20, 2025: actual —, estimate 100K USD, surprise —, Comparison unavailable. Q3 2025, reported Aug 11, 2025: actual 400K USD, estimate 6.52M USD, surprise -93.87%, Miss. Q4 2025, reported Nov 12, 2025: actual —, estimate 5.19M USD, surprise —, Comparison unavailable. Q1 2026, reported Mar 17, 2026: actual 5.4M USD, estimate 4.42M USD, surprise +22.05%, Beat. Q2 2026, reported May 13, 2026: actual 8.72M USD, estimate 4.57M USD, surprise +90.72%, Beat. Q3 2026, reported Aug 13, 2026: actual 11.38M USD, estimate 12.24M USD, surprise -7.01%, Miss. Q4 2026, reported Nov 11, 2026: actual —, estimate 15.86M USD, surprise —, Comparison unavailable.

ABEO peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding ABEO

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
9.82M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
6.96M
Weight
0.01%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
4.03M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
2.42M
Weight
0.02%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.81+0.45%
Simplify Propel Opportunities ETF logoSimplify Propel Opportunities ETFSURI
Market value
1.68M
Weight
1.98%
AUM
85.05M USD
Expense ratio
2.82%
Price / 1D
$19.8186-0.20%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
1.57M
Weight
0.01%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
903.79K
Weight
0.06%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
iShares Core S&P Total U.S. Stock Market ETF logoiShares Core S&P Total U.S. Stock Market ETFITOT
Market value
717K
Weight
0.00%
AUM
97.17B USD
Expense ratio
0.03%
Price / 1D
$167.97+0.46%

Continue in GoAI

Research ABEO

research.disclaimer